FDA, working with the Nuclear Regulatory Commission, approved NorthStar Medical Radioisotopes' RadioGenix System, a "novel manufacturing system" to produce a non-uranium version of radioisotope technetium-99m (Tc-99m), a diagnostic agent used in nuclear imaging studies to detect cancer and coronary artery disease, FDA and Commissioner Scott Gottlieb announced in simultaneous press statements on Thursday (Feb. 8). Tc-99m, used in more than 80 percent of nuclear medicine imaging procedures in the United States, is derived from molybdenum-99 (Mo-99) and up to now...